transthyretin amyloid cardiomyopathy

With post hoc analysis, BridgeBio touts case for acoramidis as FDA decision date draws near
Fierce Biotech
Mon, 09/30/24 - 09:57 am
BridgeBio
acoramidis
FDA
transthyretin amyloid cardiomyopathy
BridgeBio Pharma Shares Rise 14% on Expected Results from Heart-Disease Study
Marketwatch
Sun, 07/16/23 - 03:03 pm
BridgeBio
transthyretin amyloid cardiomyopathy
Ionis, AstraZeneca change a key trial, fueling more questions about a genetic heart disease
BioPharma Dive
Mon, 05/2/22 - 11:03 am
Ionis Pharmaceuticals
AstraZeneca
clinical trials
transthyretin amyloid cardiomyopathy
How a surprise finding made an Alnylam study one of biotech’s most ‘polarizing’ trials
BioPharma Dive
Tue, 04/26/22 - 10:31 am
Alnylam
clinical trials
Onpattro
transthyretin amyloid cardiomyopathy
AstraZeneca and Neurimmune close agreement to develop monoclonal antibody, NI006
Biopharma Reporter
Tue, 03/1/22 - 10:23 am
Alexion
AstraZeneca
Neurimmune
N!006
monoclonal antibodies
transthyretin amyloid cardiomyopathy
Bridgebio sets its heart on besting Pfizer
EP Vantage
Fri, 12/3/21 - 10:31 am
BridgeBio
Pfizer
acoramidis
Vyndaqel
amyloidosis
transthyretin amyloid cardiomyopathy
Pfizer prospects for tafamidis market
Biopharma Dive
Tue, 04/30/19 - 05:38 pm
Pfizer
tafamidis
transthyretin amyloid cardiomyopathy
FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease
CP Wire
Mon, 01/14/19 - 10:37 am
Pfizer
ATTR
transthyretin amyloid cardiomyopathy
tafamidis
FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease
Mon, 01/14/19 - 10:09 am
Pfizer
ATTR
transthyretin amyloid cardiomyopathy
tafamidis
Pfizer rare heart disease drug reduces risk of death by 30 percent in study
Reuters
Mon, 08/27/18 - 11:44 am
Pfizer
tafamidis
transthyretin amyloid cardiomyopathy